Navigation Links
Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity.' High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.

About pertuzumab Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of pertuzumab in a single agent setting had suggested clinical activity - including stable disease - in heavily pretreated patients with advanced ovarian and breast cancers. Genentech and Roche are evaluating pertuzumab in solid tumors (ovarian and breast cancers), and in combination with other therapies.

About Herceptin (trastuzumab) Herceptin is a humanised antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential. It has demonstrated efficacy in treating both early and advanced (metastatic) breast cancer. Given on its own as monotherapy as well as in combination with or following standard chemotherapy, Herceptin has been shown to improve response rates, disease-free survival and overall survival while maintaining quality of life in women with HER2-positive breast cancer.

Herceptin received approval for use in the European Union for advanced (metastatic) HER2-positive breast cancer in 2000 and for early HER2-positive breast cancer in 2006. In the advanced setting, Herceptin is now approved for use as a first-line therapy in combination with paclitaxel where anthracyclines are unsuitable, as first-line therapy in combination with docetaxel, and as a single agent in third-line therapy. In M
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... , CARTERSVILLE, Ga. ; June 2 ... Women (GASC) – Georgia ,s first fully ... minor gynecological surgeries in a true ... facility specializes in laparoscopic and other highly advanced, ...
... (Nasdaq: FHCO ) announced that it has fulfilled an order for 3.5 million ... World Cup. The 2010 World Cup will take place in The Republic of ... . , , , ... three million tickets to the games, is expected to flood the country with visitors. ...
Cached Medicine Technology:New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 3
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... and poor printing on prescription labels handed out ... to errors in taking medication, according to new ... (Canadian National Institute for the Blind)., The study, ... , found that labels on prescription medications dispensed ... guidelines for legibility. , By simply following recommended ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... Hologic, Inc.,(Nasdaq: HOLX ), a leading developer, ... and surgical products dedicated to,serving the healthcare needs ... quarter and fiscal 2008 operating results on Tuesday, ... the release, management will,host a conference call on ...
... Credentialing Center (ANCC) has designated Geisinger Medical Center (GMC) ... conference call to hospital administrators, nurses and staff who ... elite group of only 15 Pennsylvania hospitals and ... achieved Magnet status. More than 6,000 hospitals are eligible ...
... Delaying, avoiding radiation could lessen long-term side effects, study ... Using chemotherapy alone, and delaying or avoiding radiation altogether, ... progressive low-grade glioma brain tumors, according to a multi-institutional ... tumor in children. If surgery can be performed, the ...
... ANN ARBOR, Mich.---The University of Michigan received $5 million ... world,s leading resource of high-quality experimental data sets of ... to a new level. , The resource will ... can predict the effectiveness of potential new drugs, said ...
... CT adds metabolic information from PET to traditional CT ... maximized workflow ... quick return on investment, MUNICH, Germany, Oct. 10 ... new concept in,integrated imaging that provides a premium imaging ...
... ... Front Line, PHILADELPHIA, Oct. 9 ... more than,590 customer service representatives (CSRs), by rewarding them with fun,healthy activities ... 4 million inquiries a year, IBC,s CSRs are more than,just busy -- ...
Cached Medicine News:Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Chemo Alone Effective in Treating Kids' Brain Tumors 2Health News:U-M to house leading drug database 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4Health News:Independence Blue Cross Celebrates Customer Service Week 2
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
... High Throughput Screening (HTS), Analyst HT ... HTS by sharing all the detection ... AD, fluorescence intensity, fluorescence polarization, time-resolved ... seamless integration into robotic environments, including ...
... Designed for Ultra High Throughput ... multimode assay detection performance. Allows for ... from assay development by sharing all ... and HT, fluorescence intensity, fluorescence polarization, ...
Medicine Products: